Welcome to Oncimmune®
Oncimmune® was founded in 2003 to commercialise technology developed in the laboratories of Professor John Robertson, a professor of surgery at the University of Nottingham, England. Research continues in the laboratory of Professor Robertson, while development of products is funded through Oncimmune®, Ltd.
Patients
Understanding EarlyCDT®
EarlyCDT® uses a highly reliable technology of testing to identify early-stage cancer. Learn More>
EarlyCDT®—Lung Brochure
Our informative booklet of the features and benefits of EarlyCDT® for Lung cancer. Download>
What is my 5-year risk?
EarlyCDT®—Breast Brochure
Our informative booklet of the features and benefits of EarlyCDT® for Breast cancer. Download>
Providers
Who Benefits from EarlyCDT®
EarlyCDT® gives the advantage of earlier detection to patients at increased risk of developing certain cancers. Learn More>
Technology
Autoantibodies specific to cancer-related antigens are key to an early detection success. Learn More>
What are the breast cancer risk factors?
Investors
The Future of EarlyCDT®
EarlyCDT® uses patented technology to detect cancer in its early stages when the possibility of a cure is highest. Read More>
Research Partners
Understanding EarlyCDT®
Oncimmune® has attracted the interest and participation of leading cancer researchers. Learn More>
Publications
"Autoantibodies in lung cancer: possibilities for early detection and subsequent cure"
Online First Thorax October 11th 2007 12/08/08 Read more
"Autoantibodies in breast cancer: their use as an aid to early diagnosis"
Annals of Oncology March 2007 12/08/08 Read more
"Technical validation of an autoantibody test for lung cancer"
Annals of Oncology February 2010 Read more